ARID1A Suppresses R-Loop-Mediated STING-Type I Interferon Pathway Activation of Anti-Tumor Immunity

Investigators showed that ARID1A loss in murine models was sufficient to induce anti-tumor immune phenotypes observed in ARID1A mutant human cancers, including increased CD8+ T cell infiltration and cytolytic activity.